Kay, J., Jaworski, J., Wojciechowski, R., Wiland, P., Dudek, A., Krogulec, M., . . . Keystone, E. (2021). Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther.
Chicago-tyylinen lähdeviittausKay, Jonathan, et al. "Efficacy and Safety of Biosimilar CT-P17 Versus Reference Adalimumab in Subjects With Rheumatoid Arthritis: 24-week Results From a Randomized Study." Arthritis Res Ther 2021.
MLA-viiteKay, Jonathan, et al. "Efficacy and Safety of Biosimilar CT-P17 Versus Reference Adalimumab in Subjects With Rheumatoid Arthritis: 24-week Results From a Randomized Study." Arthritis Res Ther 2021.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.